Literature DB >> 28647684

Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial.

Robertino M Mera1, Luis E Bravo2, M Constanza Camargo3, Juan C Bravo2, Alberto G Delgado1, Judith Romero-Gallo1, Maria C Yepez4, José L Realpe4, Barbara G Schneider1, Douglas R Morgan1, Richard M Peek1,5,6, Pelayo Correa1, Keith T Wilson1,5,6,7,8, M Blanca Piazuelo1,7.   

Abstract

OBJECTIVE: To evaluate the long-term effect of cumulative time exposed to Helicobacter pylori infection on the progression of gastric lesions.
DESIGN: 795 adults with precancerous gastric lesions were randomised to receive anti-H. pylori treatment at baseline. Gastric biopsies were obtained at baseline and at 3, 6, 12 and 16 years. A total of 456 individuals attended the 16-year visit. Cumulative time of H. pylori exposure was calculated as the number of years infected during follow-up. Multivariable logistic regression models were used to estimate the risk of progression to a more advanced diagnosis (versus no change/regression) as well as gastric cancer risk by intestinal metaplasia (IM) subtype. For a more detailed analysis of progression, we also used a histopathology score assessing both severity and extension of the gastric lesions (range 1-6). The score difference between baseline and 16 years was modelled by generalised linear models.
RESULTS: Individuals who were continuously infected with H. pylori for 16 years had a higher probability of progression to a more advanced diagnosis than those who cleared the infection and remained negative after baseline (p=0.001). Incomplete-type IM was associated with higher risk of progression to cancer than complete-type (OR, 11.3; 95% CI 1.4 to 91.4). The average histopathology score increased by 0.20 units/year (95% CI 0.12 to 0.28) among individuals continuously infected with H. pylori. The effect of cumulative time of infection on progression in the histopathology score was significantly higher for individuals with atrophy (without IM) than for individuals with IM (p<0.001).
CONCLUSIONS: Long-term exposure to H. pylori infection was associated with progression of precancerous lesions. Individuals infected with H. pylori with these lesions may benefit from eradication, particularly those with atrophic gastritis without IM. Incomplete-type IM may be a useful marker for the identification of individuals at higher risk for cancer. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  zzm321990H. pylorizzm321990; Latin America; OLGA; OLGIM; atrophy; dysplasia; eradication; gastric cancer; intestinal metaplasia

Mesh:

Substances:

Year:  2017        PMID: 28647684      PMCID: PMC5742304          DOI: 10.1136/gutjnl-2016-311685

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

Review 1.  Gastric dysplasia: the Padova international classification.

Authors:  M Rugge; P Correa; M F Dixon; T Hattori; G Leandro; K Lewin; R H Riddell; P Sipponen; H Watanabe
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

2.  The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis.

Authors:  Lisette G Capelle; Annemarie C de Vries; Jelle Haringsma; Frank Ter Borg; Richard A de Vries; Marco J Bruno; Herman van Dekken; Jos Meijer; Nicole C T van Grieken; Ernst J Kuipers
Journal:  Gastrointest Endosc       Date:  2010-04-09       Impact factor: 9.427

3.  The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer.

Authors:  C M den Hoed; B C van Eijck; L G Capelle; H van Dekken; K Biermann; P D Siersema; E J Kuipers
Journal:  Eur J Cancer       Date:  2011-01-14       Impact factor: 9.162

4.  Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study.

Authors:  M Rugge; M de Boni; G Pennelli; M de Bona; L Giacomelli; M Fassan; D Basso; M Plebani; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  2010-02-23       Impact factor: 8.171

5.  Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice.

Authors:  Xun Cai; Jane Carlson; Calin Stoicov; Hanchen Li; Timothy C Wang; JeanMarie Houghton
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

6.  The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma.

Authors:  J R Jass; M I Filipe
Journal:  Histochem J       Date:  1981-11

7.  Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Authors:  Chung-Wei Lee; Barry Rickman; Arlin B Rogers; Zhongming Ge; Timothy C Wang; James G Fox
Journal:  Cancer Res       Date:  2008-04-25       Impact factor: 12.701

8.  A model for gastric cancer epidemiology.

Authors:  P Correa; W Haenszel; C Cuello; S Tannenbaum; M Archer
Journal:  Lancet       Date:  1975-07-12       Impact factor: 79.321

Review 9.  Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.

Authors:  Yi-Chia Lee; Tsung-Hsien Chiang; Chu-Kuang Chou; Yu-Kang Tu; Wei-Chih Liao; Ming-Shiang Wu; David Y Graham
Journal:  Gastroenterology       Date:  2016-02-02       Impact factor: 22.682

10.  The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

Authors:  Yi-Chia Lee; Tony Hsiu-Hsi Chen; Han-Mo Chiu; Chia-Tung Shun; Hung Chiang; Tzeng-Ying Liu; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Gut       Date:  2012-06-14       Impact factor: 23.059

View more
  38 in total

1.  Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis.

Authors:  Baldeep S Pabla; Shailja C Shah; Juan E Corral; Douglas R Morgan
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-30       Impact factor: 11.382

2.  Cystathionine γ-lyase exacerbates Helicobacter pylori immunopathogenesis by promoting macrophage metabolic remodeling and activation.

Authors:  Yvonne L Latour; Johanna C Sierra; Jordan L Finley; Mohammad Asim; Daniel P Barry; Margaret M Allaman; Thaddeus M Smith; Kara M McNamara; Paula B Luis; Claus Schneider; Justin Jacobse; Jeremy A Goettel; M Wade Calcutt; Kristie L Rose; Kevin L Schey; Ginger L Milne; Alberto G Delgado; M Blanca Piazuelo; Bindu D Paul; Solomon H Snyder; Alain P Gobert; Keith T Wilson
Journal:  JCI Insight       Date:  2022-06-22

Review 3.  Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.

Authors:  Zhen Luo; Mingfu Tian; Ge Yang; Qiaoru Tan; Yubing Chen; Geng Li; Qiwei Zhang; Yongkui Li; Pin Wan; Jianguo Wu
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

Review 4.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

5.  Tipping the Scale Toward Gastric Disease: A Host-Pathogen Genomic Mismatch?

Authors:  Gloria Tavera; Douglas R Morgan; Scott M Williams
Journal:  Curr Genet Med Rep       Date:  2018-10-10

Review 6.  Chemoprevention Against Gastric Cancer.

Authors:  Shailja C Shah; Richard M Peek
Journal:  Gastrointest Endosc Clin N Am       Date:  2021-07

7.  The Distribution of Incomplete Gastric Intestinal Metaplasia (GIM) Subtype among Biopsy Sites according to the Updated Sydney System and Its Association with GIM Extension.

Authors:  Duc Trong Quach; Huy Minh Le; Trung Sao Nguyen; Toru Hiyama
Journal:  Gastroenterol Res Pract       Date:  2018-05-08       Impact factor: 2.260

Review 8.  Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice.

Authors:  Shailja C Shah; Andrew J Gawron; Reem A Mustafa; M Blanca Piazuelo
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

9.  The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.

Authors:  M Blanca Piazuelo; Luis E Bravo; Robertino M Mera; M Constanza Camargo; Juan C Bravo; Alberto G Delgado; M Kay Washington; Alicia Rosero; Luz S Garcia; Jose L Realpe; Sandra P Cifuentes; Douglas R Morgan; Richard M Peek; Pelayo Correa; Keith T Wilson
Journal:  Gastroenterology       Date:  2020-11-18       Impact factor: 22.682

Review 10.  The role of polyamines in gastric cancer.

Authors:  Kara M McNamara; Alain P Gobert; Keith T Wilson
Journal:  Oncogene       Date:  2021-06-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.